Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...